Participate in Psychedelic Clinical Trials

You'll also gain access to the psychedelic industry’s most robust platform for free.

Join over 4,000 community members

Researchers

Founders

Investors

Therapists

Activists

Find the Psychedelic Courses That Can Launch Your Career

Therapists and sitters are needed to lead the growth of the psychedelic-assisted therapy that is slated to help millions.

Access and Inclusion in Psychedelic Treatment

Psychedelic-assisted therapy is making its way through the established medical system’s approval process and moving towards becoming an available treatment...

Psychedelics

Poetry, Symbols, and Story in Psychedelic Therapy

“And as imagination bodies forth the forms of things unknown, the poet’s pen turns them to shapes and gives to...

Psilocybin-Assisted Therapy: Part 2

In this course trainees receive instruction in psilocybin administration, integration, and group formats for psychedelic facilitation. Trainees are encouraged to...

Psilocybin

Community Psilocybin Harm Reduction Course

Community Psilocybin Harm Reduction Course. In this training course you will learn the benefits of harm reduction and how harm...

Psilocybin

Skylight Psychedelics Ketamine-Assisted Therapy Training + Psilocybin Training/Harm Reduction Course

Ketamine-Assisted Therapy Training PLUS Psilocybin-Assisted Therapy/Harm Reduction

Psilocybin Ketamine

Skylight Psychedelics Ketamine-Assisted Therapy Training Course

A comprehensive course for licensed therapists & providers.

Ketamine

Skylight Psychedelics Psilocybin-Assisted Therapy Training Course: The Comprehensive Harm Reduction Guide from the Underground

The Comprehensive Harm Reduction Guide from the Underground. This course is most comprehensive guide available of its kind. Designed by...

Psilocybin

Microdosing

A proven science-based process to enhance emotional balance, holistic wellness, and peak performance. Unleash your potential with the transformational power...

Psychedelics

View All Courses

Become 'Brain Healthy'

We're creating a world where every human can be more well through stronger access to critical health data.

Explore the Latest Psychedelic Research

Ketamine use in current clinical practice

… named S- and R-ketamine, with each racemate … -ketamine compared with S(+)-ketamine 2 . Several animal studies have shown that the clearance and volume of distribution of ketamine …

Ketamine

Increased global integration in the brain after psilocybin therapy for depression

… of psilocybin on brain function in two clinical trials of depression. The first was an open-label trial of orally administered psilocybin (10 … controlled trial comparing psilocybin therapy with …

Psilocybin

Rediscovering psilocybin as an antidepressive treatment strategy

… psilocybin over the period of the last 20 years. Despite the promising progress in understanding the mechanisms of psilocybin, … treatment effect sizes for psilocybin as an antidepressant. …

Psilocybin

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

… Pooled analysis of six phase 2 trials of MDMA-assisted therapy for PTSD have … of MDMA-assisted therapy in individuals with severe PTSD. Participants were given three doses of …

MDMA

Browse Psychedelics Data

Need Psychedelics Research Done for Your Organization?

Find Legal Psychedelic Therapy and Experiences

Browse through and connect with thousands of vetted practitioners currently serving people like you.

Use Neuly Care

Participate in a Clinical Trial

Find and enroll in active programs taking place around the world.

Browse Clinical Trials

Stay Informed on Psychedelic Companies

View Public Company Index

Add your Listing to Neuly

Neuly is constantly being updated, and we'd love to add your data!

Get Started

From News to Neuly

Written by Psychedelic Invest • 16 hours ago

Psyence Biomedical Announces Effective Date for 1-for-75 Share Consolidation

NEW YORK, Nov. 19, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced an effective date for its...

Written by Psychedelic Invest • 16 hours ago

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced the favorable outcome of the...

Written by Psilocybin Alpha • 1 day ago

Psychedelic Investor Survey Q3 2024

Topline results from the latest in our series of psychedelics investor surveys. ∎ In late Q3’24, we distributed our Psychedelics Investor Survey. Prior to that,...

Psychedelics

Written by Psychedelic Invest • 1 day ago

Braxia Scientific Announces Change in Directors and CEO

Toronto, Ontario–(Newsfile Corp. – November 18, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) (“Braxia”, or the “Company”) announced that Jerry...

Written by DoubleBlind Mag • 1 day ago

Down the Rabbit Hole with “White Rabbit” Mushrooms

When we think of “White Rabbit,” many of us are likely to think of Alice In Wonderland and the white rabbit who rushes in from...

Psilocybin

Written by Psychedelic Invest • 1 day ago

Lobe Sciences and Alera Pharma Announce Notice of Allowance for Second U.S. Patent for Conjugated Psilocin™

Lobe Sciences, Ltd. (“Lobe Sciences” or the “Company”) (CSE: LOBE), (OTCQB: LOBEF) and Alera Pharma, Inc. (“Alera” or “Alera Pharma”), biopharmaceutical companies focused on developing...

Psilocybin